Analyst Research

Report Title Price
Exalenz Bioscience Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy
Exalenz Bioscience Ltd. (EXEN) - Financial and Strategic SWOT Analysis Review
Provider: GlobalData
$125.00
Buy
Exalenz Bioscience Ltd. (EXEN) - Medical Equipment - Deals and Alliances Profile
Provider: GlobalData
$250.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Exalenz Bioscience Ltd Announces FDA Approval For Clinical Experiments


Wednesday, 7 Sep 2011 08:00pm EDT 

Exalenz Bioscience Ltd announced that it has received approval from the US Food and Drug Administration to carry out clinical experiments which apply to the field of HCC (Hepatocellular Carcinoma), which is one of the most common forms of liver cancer. The approval applies to clinical experiments which will take place in five medical centers, three in the United States, one in Canada and one in Israel. 

Latest Developments for Exalenz Bioscience Ltd

Latest Key Developments in Medical

Company Quote

Exalenz Bioscience Ltd
(EXEN.TA)
12.5
0.1 +0.81%
16 May 2013